Drugs / KSQ-001EX
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06237881 | Jan 2024 → Jan 2027 expected | head and neck neoplasm, lung neoplasm, melanoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KSQ-001EX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06237881 ↗ |
| Action | Inhibit | “Engineered to Inactivate the SOCS1 Gene” NCT06237881 ↗ |
| Modality | Cell therapy | “Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene” NCT06237881 ↗ |
| Target | SOCS1 | “Inactivate the SOCS1 Gene” NCT06237881 ↗ |